CERT vs. DH, HIMS, MOR, QDEL, MLTX, LTH, INDV, IMCR, ACAD, and OLK
Should you be buying Certara stock or one of its competitors? The main competitors of Certara include Definitive Healthcare (DH), Hims & Hers Health (HIMS), MorphoSys (MOR), QuidelOrtho (QDEL), MoonLake Immunotherapeutics (MLTX), Life Time Group (LTH), Indivior (INDV), Immunocore (IMCR), ACADIA Pharmaceuticals (ACAD), and Olink Holding AB (publ) (OLK). These companies are all part of the "medical" sector.
Certara (NASDAQ:CERT) and Definitive Healthcare (NASDAQ:DH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
Certara received 2 more outperform votes than Definitive Healthcare when rated by MarketBeat users. Likewise, 34.92% of users gave Certara an outperform vote while only 31.25% of users gave Definitive Healthcare an outperform vote.
Certara has a net margin of -15.62% compared to Definitive Healthcare's net margin of -80.40%. Certara's return on equity of 4.33% beat Definitive Healthcare's return on equity.
Certara presently has a consensus price target of $20.06, indicating a potential upside of 23.77%. Definitive Healthcare has a consensus price target of $11.31, indicating a potential upside of 60.69%. Given Definitive Healthcare's higher possible upside, analysts plainly believe Definitive Healthcare is more favorable than Certara.
74.0% of Certara shares are held by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are held by institutional investors. 2.6% of Certara shares are held by insiders. Comparatively, 15.3% of Definitive Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Certara has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Definitive Healthcare has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.
Certara has higher revenue and earnings than Definitive Healthcare. Certara is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
In the previous week, Definitive Healthcare had 2 more articles in the media than Certara. MarketBeat recorded 4 mentions for Definitive Healthcare and 2 mentions for Certara. Definitive Healthcare's average media sentiment score of 1.09 beat Certara's score of 0.55 indicating that Definitive Healthcare is being referred to more favorably in the news media.
Summary
Certara beats Definitive Healthcare on 12 of the 18 factors compared between the two stocks.
Get Certara News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
